Sur R K, Pacella J A, Donde B, Levin C V, Cooper K
Department of Radiation Oncology, University of the Witwatersrand, Johannesburg.
S Afr J Surg. 1997 Nov;35(4):206-9.
Twenty-five patients with malignant invasive stage III thymomas who underwent biopsy for tissue diagnosis were treated with primary radiotherapy (mean dose 46.36 Gy, range 32.4-58 Gy). These patients were followed up for a period of 10 years and survival/failure analysis was performed. Five prognostic variables were compared using the log rank test. There was no difference in survival between ages less than 50 and more than 50 years, presence or absence of myasthenia gravis, sex, histology and race. The mean follow-up was 39 months (range 1-86 months). The 5-year disease-free survival was 81% overall survival 72% and local failure rate 13%. Most local failures occurred in the first 3 months. Six patients died after a course of radiotherapy (2 intrathoracic relapse, 1 disseminated disease, 1 local failure and distant metastasis, 2 causes not related to disease). Hilar fibrosis was seen in 4 patients who are asymptomatic. No other complications were recorded. Radical external beam radiotherapy alone can give good results in malignant stage III invasive thymomas.
25例Ⅲ期恶性浸润性胸腺瘤患者接受活检以进行组织诊断，随后接受了根治性放疗（平均剂量46.36Gy，范围32.4 - 58Gy）。对这些患者进行了为期10年的随访，并进行了生存/失败分析。使用对数秩检验比较了五个预后变量。年龄小于50岁和大于50岁、有无重症肌无力、性别、组织学类型和种族之间的生存率无差异。平均随访时间为39个月（范围1 - 86个月）。5年无病生存率为81%，总生存率为72%，局部失败率为13%。大多数局部失败发生在放疗后的前3个月。6例患者在放疗疗程后死亡（2例为胸内复发，1例为播散性疾病，1例为局部失败并远处转移，2例死因与疾病无关）。4例患者出现肺门纤维化，但无症状。未记录到其他并发症。单纯根治性外照射放疗对Ⅲ期恶性浸润性胸腺瘤可取得良好效果。
